Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trialReport as inadecuate




Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial - Download this document for free, or read online. Document in PDF available to download.

Breast Cancer Research and Treatment

, Volume 155, Issue 1, pp 99–107

First Online: 09 December 2015Received: 24 November 2015Accepted: 26 November 2015DOI: 10.1007-s10549-015-3652-4

Cite this article as: Hanai, A., Ishiguro, H., Sozu, T. et al. Breast Cancer Res Treat 2016 155: 99. doi:10.1007-s10549-015-3652-4

Abstract

Research on patient-reported outcomes indicates that constipation is a common adverse effect of chemotherapy, and the use of 5-hydroxytryptamine serotonin; 5HT3 receptor antagonists aggravates this condition. As cancer patients take multiple drugs as a part of their clinical management, a non-pharmacological self-management SM of constipation would be recommended. We aimed to evaluate the effectiveness of a SM program on antiemetic-induced constipation in cancer patients. Thirty patients with breast cancer, receiving 5HT3 receptor antagonists to prevent emesis during chemotherapy were randomly assigned to the intervention or control group. The SM program consisted of abdominal massage, abdominal muscle stretching, and education on proper defecation position. The intervention group started the program before the first chemotherapy cycle, whereas patients in the wait-list control group received the program on the day before their second chemotherapy cycle. The primary outcome was constipation severity, assessed by the constipation assessment scale CAS, sum of eight components. The secondary outcome included each CAS component 0–2 points and mood states. A self-reported assessment of satisfaction with the program was performed. The program produced a statistically and clinically significant alleviation of constipation severity mean difference in CAS, −3.00; P = 0.02, decrease in the likelihood of a small volume of stool P = 0.03, and decrease in depression and dejection P = 0.02. With regards to program satisfaction, 43.6 and 26.4 % patients rated the program as excellent and good, respectively. Our SM program is effective for mitigating the symptoms of antiemetic-induced constipation during chemotherapy.

KeywordsConstipation Antiemetic Breast cancer Supportive care Exercise Self-management Electronic supplementary materialThe online version of this article doi:10.1007-s10549-015-3652-4 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Akiko Hanai - Hiroshi Ishiguro - Takashi Sozu - Moe Tsuda - Hidenori Arai - Akira Mitani - Tadao Tsuboyama

Source: https://link.springer.com/







Related documents